- Home
- SEV vs BDTX Comparison
SEV vs BDTX Comparison
Compare SEV & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEV | BDTX |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | 46 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.2M | 116.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SEV | BDTX |
|---|---|---|
| Price | $2.96 | $3.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 238.0K | ★ 757.8K |
| Earning Date | 05-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,757.14 | N/A |
| P/E Ratio | ★ N/A | $8.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $1.46 |
| 52 Week High | $11.24 | $4.94 |
Technical Indicators
Market Signals| Indicator | SEV | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 65.80 |
| Support Level | $2.37 | $3.02 |
| Resistance Level | $3.26 | $3.37 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 35.80 | 68.06 |
Price Performance
Historical ComparisonAbout SEV Aptera Motors Corp.
Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.